Co-administration of the long-acting monoclonal antibody AZD7442 and bivalent Ancestral/BA.1 vaccination is well-tolerated in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus: the results of the multicentre, open-label,
Abstract Immunocompromised individuals remain at risk of severe COVID-19. This multicentre, open-label, phase II randomised controlled trial evaluated the safety, pharmacokinetics and immunogenicity of co-administering the long-acting monoclonal antibody AZD7442 with a bivalent (Ancestral/BA.1) mRNA/LNP SARS-CoV-2 vaccine. A total of 139 immunocompromised adults received AZD7442 followed 28 days later by vaccination. AZD7442 was well tolerated, with no serious adverse events. Serum AZD7442 concentrations peaked at day 28 and remained detectable across disease cohorts at day 180. Anti-Spike antibody responses increased after AZD7442 and reached their highest levels after vaccination. Although binding antibodies against Omicron variants increased post-vaccination, neutralisation of Omicron remained limited after both AZD7442 and vaccination. Vaccination preferentially boosted antibodies targeting S2, the S1 N-terminal domain and receptor-binding domain epitopes not bound by AZD7442, and increased S2-specific memory B cells. Vaccine-induced T-cell responses were cross-reactive between ancestral and Omicron variants. Our findings support consideration of combined antibody and vaccine strategies in future therapeutic antibody development. The trial is registered with the International Standard Randomised Controlled Trial Number registry (ISRCTN53507177).
Authors
- Keith M. O. Wilson (ORCID: https://orcid.org/0000-0002-6327-9366)
- Steven Knapper (ORCID: https://orcid.org/0000-0002-6405-4441)
- Kerenza Hood (ORCID: https://orcid.org/0000-0002-5268-8631)
- Katie JM Jeffery (ORCID: https://orcid.org/0000-0002-6506-2689)
- Catharine Porter (ORCID: https://orcid.org/0000-0003-1851-0677)
- Paola Cicconi (ORCID: https://orcid.org/0000-0001-6347-966X)
- Eleanor J. Barnes (ORCID: https://orcid.org/0000-0002-0860-0831)
- Emma Thomas‐Jones (ORCID: https://orcid.org/0000-0001-7716-2786)
- Adrian V. S. Hill (ORCID: https://orcid.org/0000-0003-0900-9629)
- Nicole Frumento (ORCID: https://orcid.org/0000-0002-1697-7110)
- Mark H. Tuthill (ORCID: https://orcid.org/0000-0002-2099-5709)
- Joanne Euden (ORCID: https://orcid.org/0000-0002-2844-6878)
- Melissa Govender (ORCID: https://orcid.org/0000-0001-8327-5517)
- Debbie Harris (ORCID: https://orcid.org/0000-0002-7073-7724)
- Stephen M. Laidlaw (ORCID: https://orcid.org/0000-0002-7970-6174)
- Melanie Varley (ORCID: https://orcid.org/0000-0002-5702-9205)
- Shirley Pringle (ORCID: https://orcid.org/0000-0003-4950-9732)
- Larry Raisanen (ORCID: https://orcid.org/0009-0001-3657-8184)
- Rebecca Tangney (ORCID: https://orcid.org/0009-0008-9573-6681)
- Georgina Meacham (ORCID: https://orcid.org/0000-0003-1929-4152)
- Miles W. Carroll (ORCID: https://orcid.org/0000-0002-7026-7187)
- Christian H. H. Ottensmeier (ORCID: https://orcid.org/0000-0003-3619-1657)
- Ernest Choy (ORCID: https://orcid.org/0000-0003-4459-8609)
- Siân Griffin (ORCID: https://orcid.org/0000-0001-5860-9036)
- Craig Bodman
- Vivien Dagley
- Jordon Rolt (ORCID: https://orcid.org/0009-0003-8037-0342)
- Susanna Shier
- Richard Adams
- Alexander Tridgell (ORCID: https://orcid.org/0000-0002-6195-0849)
- Lisette Nixon
- Victoria Walker
Institutions
- Cardiff and Vale University Health Board (GB)
- Centre for Human Genetics (GB)
- University Hospital of Wales (GB)
- Oxford Health NHS Foundation Trust (GB)
- Clatterbridge Cancer Centre NHS Foundation Trust (GB)
- University of Oxford (GB)
- NIHR Oxford Musculoskeletal Biomedical Research Centre (GB)
- Oxford BioMedica (United Kingdom) (GB)
- Oxford University Hospitals NHS Trust (GB)
- Jenner Institute (GB)
- Liverpool University Hospitals NHS Foundation Trust (GB)
- Cardiff University (GB)
Publication Details
- Journal
- Nature Communications
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1038/s41467-026-78637-z
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Health and Care Research Wales
- National Institute for Health and Care Research
- University of Oxford